Indication
Glycogen Storage Disease Type III
1 clinical trial
4 products
Clinical trial
A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD IIIStatus: Terminated, Estimated PCD: 2023-03-20
Product
H2 BlockerProduct
UX053Product
AntipyreticProduct
H1 Blocker